Company Overview - The company is an innovative biopharmaceutical enterprise, with all products currently in the research and development stage and no commercial sales initiated yet[7]. - The company has not yet commenced commercial production or sales of its products, which are still in the research and development phase[125]. - The company’s stock is listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board under the ticker 688443[38]. Product Development and R&D - Multiple products, including GR1501, GR1801, and GR1802, are expected to be launched within the next three years, with a professional sales team being established to support this[7]. - The company has submitted new drug applications for several monoclonal antibodies, including GR1603, GR1801, and GR2002, marking significant milestones in clinical trials[4]. - The company has developed multiple monoclonal antibodies and bispecific antibodies, including GR1501, GR1603, and GR2002, which are currently in various stages of research[40]. - The company is focusing on developing new antibody drugs, including monoclonal antibodies and their derivatives, to address critical disease areas[77]. - The company is actively pursuing clinical trials for various indications, with several products at different stages of development[56]. - The company has 12 products in its research pipeline, all of which are independently developed, targeting autoimmune diseases, infectious diseases, and tumors[79]. - The company has established a full-chain platform from molecular discovery to industrialization, aiming to provide reliable and affordable innovative biopharmaceuticals[55]. - The company has developed a new phage display system for monoclonal antibody discovery and a technology platform for bispecific antibody discovery[54]. - The company has a robust process development platform for recombinant antibody drugs, enhancing its drug development efficiency[54]. - The company has developed a high-efficiency recombinant antibody drug process development platform[54]. - The company has established a comprehensive process for rapid and robust process development in its R&D efforts[97]. - The company has implemented a comprehensive procurement management system to ensure standardized procurement processes[58]. Financial Performance - The company reported a net loss attributable to shareholders, excluding non-recurring gains and losses, which increased significantly compared to the same period last year due to substantial R&D investments and increased share-based payment expenses[49]. - The company's operating revenue for the first half of the year was CNY 132,804.13, a significant decrease compared to CNY 451,259.66 in the same period last year[59]. - The net profit attributable to shareholders was a loss of CNY 388,154,683.30, compared to a loss of CNY 257,605,172.35 in the previous year[59]. - The net cash flow from operating activities was a negative CNY 182,942,333.55, worsening from a negative CNY 85,381,551.16 in the same period last year[59]. - R&D expenditure accounted for a significant portion of the company's cash outflows during the reporting period, reflecting the ongoing development of multiple new drug products[40]. - The company's total assets and net assets attributable to shareholders increased compared to the end of the previous year, primarily due to funds raised from the initial public offering[49]. - The company's revenue recognition policy confirms revenue when control of goods or services is transferred to the customer[148]. Market Strategy and Risks - The company is committed to conducting in-depth market research and developing competitive pricing strategies to enhance market penetration of its products[2]. - The company is focusing on collaboration with established partners to accelerate market access for its new drugs[2]. - The company has identified potential risks related to its ongoing R&D and market expansion efforts, which may impact its financial condition[16]. - There are risks associated with the clinical trial progress and market promotion of the company's products, which may not meet expectations[126][128]. - The company is committed to meeting unmet clinical needs in the market through continuous innovation[55]. Industrialization and Production Capacity - The company plans to expand its antibody industrialization base, which will add 40,000L of bioreactor capacity, aimed at reducing production costs and achieving economies of scale[12]. - The company has established a production scale of 4,400L for antibody raw liquid and is expanding its capacity by adding 20,000L of fermentation capacity[72]. - The company has initiated a project to upgrade its antibody industrialization base to support large-scale commercial production of its products[72]. - The company’s antibody industrialization base is located in Chongqing International Bio-city, with the first phase completed in 2019 and receiving production licenses[98]. Environmental and Compliance Measures - The company has invested 48.23 million in environmental protection during the reporting period[138]. - The company has implemented environmental monitoring measures, including annual monitoring of total volatile organic compounds and other pollutants[154]. - The company has not implemented any carbon reduction measures during the reporting period[123]. - The company has taken measures to reduce carbon emissions, although specific effects were not detailed in the report[156]. - The company’s environmental facilities have been operating normally during the reporting period[151]. Shareholder Commitments and Regulations - The company commits not to transfer or delegate management of its shares for 36 months post-IPO approval[170]. - Shareholders are restricted from selling shares at a price lower than the IPO price during the lock-up period[172]. - The company will not reduce its shareholding until it achieves profitability, which is expected to be within three complete fiscal years post-IPO[172]. - If the stock price falls below the IPO price for 20 consecutive trading days, the lock-up period will automatically extend by 6 months[172]. - Shareholders can only sell up to 25% of their total shares annually while in management positions[172]. - The company will adhere to all relevant regulations regarding share transfer and lock-up periods[172]. - Any gains from buying and selling shares within 6 months will be returned to the company[172]. - The company will not reduce shareholding if it is under investigation for major violations or if it is at risk of delisting[172]. - The company plans to gradually reduce shareholding after the lock-up period, considering market stability and operational needs[172]. - Shareholders must report any changes in their shareholding status during their tenure[172]. - Core technical personnel are restricted to transferring no more than 25% of their shares annually during their tenure and for 6 months post-departure[177]. - The lock-up period for shares held by core technical personnel extends for 4 years, with annual transfers capped at 25% of their total shares prior to the IPO[177]. - If the company is unprofitable, core personnel cannot reduce their holdings for 3 full fiscal years post-IPO[177]. - The company will adhere to legal and regulatory requirements regarding share lock-up periods and transfer conditions[177]. - Any share reduction must comply with the company's stock issuance price and adjusted prices post-dividend or capital increase events[180]. - The company emphasizes long-term support for its business outlook and plans to hold shares post-lock-up[180]. - The company will ensure stable operations and disclose control arrangements during any share reduction process[180].

证券代码：智翔金泰 证券简称：688443 公告编号：2023-013 重庆智翔金泰生物制药股份有限公司（以下简称"公司"）已于 2023 年 8 月 31 日发布公司 2023 半年度报告，为便于广大投资者更全面深入地了解公司 2023 半年度经营成果、财务状况、发展理念，公司参与了由上交所主办的 2023 半年度 制药及生物制品行业集体业绩说明会，此次活动将采用网络文字互动的方式举行， 投资者可登录上海证券交易所上证路演中心（http://roadshow.sseinfo.com/）参与线 上互动交流。 一、说明会类型 本次投资者说明会以网络文字互动形式召开，公司将针对 2023 半年度的经营 成果及财务指标的具体情况与投资者进行互动交流和沟通，在信息披露允许的范围 内就投资者普遍关注的问题进行回答。 二、说明会召开的时间、地点 （一）会议线上交流时间：2023 年 9 月 7 日(星期四)下午 13:00-15:00 重庆智翔金泰生物制药股份有限公司 关于参加 2023 半年度制药及生物制品行业 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对 ...

证券代码：688443 证券简称：智翔金泰 公告编号：2023-009 重庆智翔金泰生物制药股份有限公司 2023 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2023 年 8 月 8 日 （二）股东大会召开的地点：重庆市江北区金源路 9 号重庆君豪大饭店 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其 持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 16 | | --- | --- | | 普通股股东人数 | 16 | | 2、出席会议的股东所持有的表决权数量 | 255,630,615 | | 普通股股东所持有表决权数量 | 255,630,615 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 69.7149 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 69.7149 | 3、董事会秘书 ...

上海市锦天城律师事务所 关于重庆智翔金泰生物制药股份有限公司 2023 年第一次临时股东大会的 法律意见书 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于重庆智翔金泰生物制药股份有限公司 2023 年第一次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9、11、12 层 电话：021-20511000 传真：021-20511999 邮编：200120 致：重庆智翔金泰生物制药股份有限公司 上海市锦天城律师事务所（以下简称"本所"）接受重庆智翔金泰生物制药股份有限 公司（以下简称"公司"）的委托，就公司召开 2023 年第一次临时股东大会（以下简称 "本次股东大会"）的有关事宜，根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会规则（2022 年 修订）》（以下简称"《上市公司股东大会规则》"）等法律、法规、规章和其他规范性文 件以及《重庆智翔金泰生物制药股份有限公司章程》（以下简称"《公司章程》"）的有关 规定，出具本法律意见书。 为出具本法律意见书，本所及本所律师依据《律师事 ...

股票简称：智翔金泰 股票代码：688443 重庆智翔金泰生物制药股份有限公司 Chongqing Genrix Biopharmaceutical Co., Ltd. （重庆市巴南区麻柳大道 699 号 2 号楼 A 区） 首次公开发行股票 科创板上市公告书 保荐人（主承销商） 上海市广东路 689 号 二〇二三年六月十九日 特别提示 重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"、"发行人"、 "公司"、"本公司"）股票将于 2023 年 6 月 20 日在上海证券交易所科创板上市。 本公司提醒投资者应充分了解股票市场风险及本公司披露的风险因素，在新 股上市初期切忌盲目跟风"炒新"，应当审慎决策、理性投资。 1 第一节 重要声明与提示 一、重要声明 本公司及全体董事、监事、高级管理人员保证上市公告书所披露信息的真实、 准确、完整，承诺上市公告书不存在虚假记载、误导性陈述或重大遗漏，并依法 承担法律责任。 上海证券交易所、有关政府机关对本公司股票上市及有关事项的意见，均不 表明对本公司的任何保证。 本 公 司 提 醒 广 大 投 资 者 认 真 阅 读 刊 载 于 上 海 证 券 交 易 所 网 站 ...

重庆智翔金泰生物制药股份有限公司 Chongqing Genrix Biopharmaceutical Co., Ltd. （重庆市巴南区麻柳大道 699 号 2 号楼 A 区） 本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点,投资者面临较大的市场风险。投 资者应充分了解科创板的投资风险及本公司所披露的风险因素，审慎作 出投资决定。 首次公开发行股票并在科创板上市 招股说明书 保荐人（主承销商） 上海市广东路 689 号 重庆智翔金泰生物制药股份有限公司 招股说明书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 发行人及全体董事、监事、高级管理 ...

重庆智翔金泰生物制药股份有限公司 首次公开发行股票并在科创板上市 发行结果公告 保荐人(主承销商)：海通证券股份有限公司 特别提示 重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"、"发行人" 或"公司"）首次公开发行人民币普通股（A 股）并在科创板上市（以下简称"本 次发行"）的申请已经上海证券交易所科创板股票上市委员会审议通过，并已经 中国证券监督管理委员会（以下简称"证监会"）同意注册（证监许可〔2023〕 725 号）。海通证券股份有限公司（以下简称"海通证券"或"保荐人（主承销 商）"）担任本次发行的保荐人（主承销商）。发行人股票简称为"智翔金泰"， 扩位简称为"智翔金泰"，股票代码为"688443"。 发行人和保荐人（主承销商）综合评估公司合理投资价值、可比公司二级市 场估值水平、所属行业二级市场估值水平等方面，充分考虑网下投资者有效申购 倍数、市场情况、募集资金需求及承销风险等因素，协商确定本次发行价格为 37.88 元/股，发行数量为 9,168.0000 万股，全部为新股发行，无老股转让。 本次发行初始战略配售数量为 458.4000 万股，占本次发行数量的 5.00%。参 与战略配售 ...

首次公开发行股票并在科创板上市 发行公告 保荐人（主承销商）：海通证券股份有限公司 重要提示 重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"、"发行人"或"公 司"）根据中国证券监督管理委员会（以下简称"中国证监会"、"证监会"）颁布的 《证券发行与承销管理办法》（证监会令〔第 208 号〕）（以下简称"《管理办 法》"）、《首次公开发行股票注册管理办法》（证监会令〔第 205 号〕）（以下 简称"《注册办法》"），上海证券交易所（以下简称"上交所"）颁布的《上海证 券交易所首次公开发行证券发行与承销业务实施细则》（上证发〔2023〕33 号） （以下简称"《实施细则》"）、《上海市场首次公开发行股票网上发行实施细则》 （上证发〔2023〕35 号）（以下简称"《网上发行实施细则》"）、《上海市场首 次公开发行股票网下发行实施细则》（上证发〔2023〕36 号）（以下简称"《网 下发行实施细则》"），中国证券业协会颁布的《首次公开发行证券承销业务规 则》（中证协发〔2023〕18 号）（以下简称"《承销业务规则》"）、《首次公开 发行证券网下投资者管理规则》（中证协发〔2023〕19 号）（以下简称" ...

（重庆市巴南区麻柳大道 699 号 2 号楼 A 区） 招股意向书 本次发行股票拟在科创板上市，科创板公司具有研发投入大、经营风险 高、业绩不稳定、退市风险高等特点,投资者面临较大的市场风险。投 资者应充分了解科创板的投资风险及本公司所披露的风险因素，审慎作 重庆智翔金泰生物制药股份有限公司 Chongqing Genrix Biopharmaceutical Co., Ltd. 首次公开发行股票并在科创板上市 保荐人（主承销商） 上海市广东路 689 号 出投资决定。 重庆智翔金泰生物制药股份有限公司 招股意向书 发行人声明 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对发行 人注册申请文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其 对发行人的盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任 何与之相反的声明均属虚假不实陈述。 根据《证券法》规定，股票依法发行后，发行人经营与收益的变化，由发行 人自行负责；投资者自主判断发行人的投资价值，自主作出投资决策，自行承担 股票依法发行后因发行人经营与收益变化或者股票价格变动引致的投资风险。 发行人及全体董事、监事、高级管理 ...

重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"、"发行人" 或"公司"）首次公开发行股票并在科创板上市的申请已经上海证券交易所（以 下简称"上交所"）科创板上市委员会审议通过，并已经中国证券监督管理委员会 （以下简称"中国证监会"）证监许可〔2023〕725 号文同意注册。《重庆智翔 金泰生物制药股份有限公司首次公开发行股票并在科创板上市招股意向书》及附 录在上海证券交易所网站（http://www.sse.com.cn/）和符合中国证监会规定条件 网站（中证网，网址 www.cs.com.cn；中国证券网，网址 www.cnstock.com；证 券时报网，网址 www.stcn.com；证券日报网，网址 www.zqrb.cn）披露，并置备 于发行人、上交所、本次发行保荐人（主承销商）海通证券股份有限公司的住所， 供公众查阅。 敬请投资者重点关注本次发行流程、网上网下申购及缴款、弃购股份处理等 方面，并认真阅读同日披露于上海证券交易所网站和符合中国证监会规定条件网 站上的《重庆智翔金泰生物制药股份有限公司首次公开发行股票并在科创板上市 发行安排及初步询价公告》。 | | 发行人基本情况 | | | ...